Related Experiment Video

Updated: May 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Escalated BEACOPP in advanced Hodgkin's lymphoma

Olivier Casasnovas1, Bertrand Coiffier

  • 1Hôpital le Bocage, Dijon, France.

Lancet (London, England)
|April 7, 2012
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Last Updated: May 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Articles linked to this work by shared authors, journal, and citation graph.

Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d'Enregistrement et Suivi des patients traités par CAR-T cells) registry.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2025

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Blood·2025

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Blood advances·2025

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

British journal of haematology·2025

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.

Nature cancer·2025

Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials.

European journal of nuclear medicine and molecular imaging·2025

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Pathogenic Airway Bacteria and Local Immune Responses During Early-Life Asthma-Like Episodes.

Allergy·2026

Exploring the potential benefits of allergen immunotherapy beyond respiratory allergy.

Expert opinion on biological therapy·2026

Rituximab remodels the circulating immune landscape in pemphigus vulgaris revealed by high-dimensional immune profiling.

Journal of translational autoimmunity·2026

Bronchoalveolar Lavage Fluid α Amylase Level a Promising Biomarker of Aspiration Syndrome: A Pilot Study.

Infection and drug resistance·2026

Artificial Intelligence in Paediatric Allergy: From Diagnostic Support to Precision Medicine.

Cureus·2026

Phenotyping immune sensitization reveals pattern-based association with post-lung transplant complications.

JHLT open·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us